Literature DB >> 27484692

Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Patrycja Kleczkowska1, Irena Smaga2, Małgorzata Filip3, Magdalena Bujalska-Zadrozny4.   

Abstract

Cannabinoids are still classified as illegal psychoactive drugs despite their broad and increasingly acknowledged therapeutic potential. These substances are most famous for their wide recreational use, particularly among young adults to either alter the state of consciousness, intensify pleasure induced by other psychoactive substances or as an alternative to the previously abused drugs. It is important to emphasize that cannabinoids are often taken together with a variety of medications intended for the treatment of alcohol use disorder (AUD) or alcohol withdrawal syndrome (AWS). These medications include disulfiram, acamprosate, and naltrexone. In this paper, we summarize recent advances in the knowledge of possible beneficial effects and interactions between cannabinoids and drugs commonly used for treatment of AUD and AWS either comorbid or existing as a separate disorder.

Entities:  

Keywords:  Alcohol abstinence; Alcohol withdrawal drugs; Cannabinoid; Interactions

Mesh:

Substances:

Year:  2016        PMID: 27484692     DOI: 10.1007/s12640-016-9655-z

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  221 in total

1.  A randomised, double-blind, placebo-controlled, efficacy study of nalmefene, as-needed use, in patients with alcohol dependence.

Authors:  Antoni Gual; Yuan He; Lars Torup; Wim van den Brink; Karl Mann
Journal:  Eur Neuropsychopharmacol       Date:  2013-04-03       Impact factor: 4.600

2.  Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans.

Authors:  Mohini Ranganathan; Michelle Carbuto; Gabriel Braley; Jaqueline Elander; Edward Perry; Brian Pittman; Rajiv Radhakrishnan; Richard A Sewell; Deepak C D'Souza
Journal:  Int J Neuropsychopharmacol       Date:  2012-01-16       Impact factor: 5.176

3.  Management of alcohol withdrawal delirium. An evidence-based practice guideline.

Authors:  Michael F Mayo-Smith; Lee H Beecher; Timothy L Fischer; David A Gorelick; Jeanette L Guillaume; Arnold Hill; Gail Jara; Chris Kasser; John Melbourne
Journal:  Arch Intern Med       Date:  2004-07-12

4.  Propranolol versus diazepam in the management of the alcohol withdrawal syndrome: double-blind controlled trial.

Authors:  T M Worner
Journal:  Am J Drug Alcohol Abuse       Date:  1994       Impact factor: 3.829

5.  The opioid antagonist naltrexone reduces the reinforcing effects of Delta 9 tetrahydrocannabinol (THC) in squirrel monkeys.

Authors:  Zuzana Justinova; Gianluigi Tanda; Patrik Munzar; Steven R Goldberg
Journal:  Psychopharmacology (Berl)       Date:  2003-12-11       Impact factor: 4.530

Review 6.  New developments for the pharmacological treatment of alcohol withdrawal syndrome. A focus on non-benzodiazepine GABAergic medications.

Authors:  Lorenzo Leggio; George A Kenna; Robert M Swift
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-10-04       Impact factor: 5.067

7.  A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence.

Authors:  B J Mason; E C Ritvo; R O Morgan; F R Salvato; G Goldberg; B Welch; E Mantero-Atienza
Journal:  Alcohol Clin Exp Res       Date:  1994-10       Impact factor: 3.455

8.  Etiology and weekly occurrence of alcohol-related seizures.

Authors:  Niels K Rathlev; Andrew Ulrich; Ted C Shieh; Michael G Callum; Edward Bernstein; Gail D'Onofrio
Journal:  Acad Emerg Med       Date:  2002-08       Impact factor: 3.451

9.  Pregabalin for alcohol dependence: a critical review of the literature.

Authors:  Riccardo Guglielmo; Giovanni Martinotti; Massimo Clerici; Luigi Janiri
Journal:  Adv Ther       Date:  2012-11-05       Impact factor: 3.845

Review 10.  GABAB receptor ligands for the treatment of alcohol use disorder: preclinical and clinical evidence.

Authors:  Roberta Agabio; Giancarlo Colombo
Journal:  Front Neurosci       Date:  2014-06-06       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.